MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.98
-0.81
-4.82%
After Hours: 16.37 +0.39 +2.44% 16:09 05/24 EDT
OPEN
16.65
PREV CLOSE
16.79
HIGH
16.93
LOW
15.88
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
28.06
52 WEEK LOW
15.16
MARKET CAP
2.58B
P/E (TTM)
-12.0241
1D
5D
1M
3M
1Y
5Y
Acadia shares to spike with a positive AdCom vote for pimavanserin next month - Citi
As neurology-focused biotech Acadia Pharma (NASDAQ:ACAD) prepares for an AdCom meeting next month on its marketing application for pimavanserin in Alzheimer’s disease psychosis (ADP), Citi argued on Thursday that the
Seekingalpha · 5d ago
Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
With the business potentially at an important milestone, we thought we'd take a closer look at ACADIA Pharmaceuticals...
Simply Wall St. · 5d ago
ACADIA Pharmaceuticals's Return On Capital Employed Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06 million.
Benzinga · 6d ago
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Zacks · 05/05 14:06
--RBC Capital Adjusts ACADIA Pharmaceuticals' Price Target to $32 From $34, Maintains Outperform Rating
MT Newswires · 05/05 08:26
--Berenberg Bank Adjusts ACADIA Pharmaceuticals' Price Target to $24 From $26, Maintains Hold Rating
MT Newswires · 05/05 07:44
ACADIA Pharma net loss widens ~70% but reiterates 2022 guidance
ACADIA Pharma's (NASDAQ:ACAD) Q1 2022 results missed on the top and bottom lines, but the company reiterated previous guidance ranges. ACADIA's (ACAD) net loss widened ~70% to ~$113M ($0.70 per
Seekingalpha · 05/04 23:01
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:15
More
No Data
Learn about the latest financial forecast of ACAD. Analyze the recent business situations of Acadia Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
28.57%Buy
57.14%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACAD stock price target is 28.89 with a high estimate of 37.00 and a low estimate of 20.00.
High37.00
Average28.89
Low20.00
Current 15.98
EPS
Actual
Estimate
-0.56-0.42-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 396
Institutional Holdings: 164.27M
% Owned: 101.76%
Shares Outstanding: 161.43M
TypeInstitutionsShares
Increased
70
5.49M
New
41
7.39M
Decreased
93
8.44M
Sold Out
28
588.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Biggar
President
Srdjan Stankovic
Chief Executive Officer/Chief Financial Officer/Director
Stephen Davis
Chief Financial Officer/Executive Vice President
Mark Schneyer
Chief Operating Officer/Executive Vice President
Brendan Teehan
Executive Vice President/General Counsel/Secretary
Austin Kim
Senior Vice President/Chief Marketing Officer
Charmaine Lykins
Senior Vice President
Amanda Morgan
Director
Elizabeth Garofalo
Independent Director
Julian Baker
Independent Director
Laura Brege
Independent Director
James Daly
Independent Director
Edmund Harrigan
Independent Director
Daniel Soland
No Data
No Data
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.